Beijing Foyou Pharma (601089.SH): Diethylammonium adenosine enteric-coated tablets obtained drug registration certificate.

18:05 07/04/2026

Fuyuan Pharmaceutical (601089.SH) announced that recently, the company has received the Drug Registration Certificate for Adenosine Disodium Diammonium Enteric-coated Tablets [Specification: 0.5g (calculated as CHNOS)] issued by the National Medical Products Administration, approving the production of the drug.

Beijing Foyou Pharma (601089.SH) announced that the company recently received the "Drug Registration Certificate" (Certificate Number: 2026S00932) issued by the National Medical Products Administration for the production of adenine arabinoside enteric-coated tablets [specification: 0.5g (calculated as CHNOS)]. The adenine arabinoside enteric-coated tablets developed by ABBOTT were approved by the National Medical Products Administration in November 1996 and have been marketed in China. This product is suitable for intrahepatic cholestasis before and caused by liver cirrhosis. This drug is suitable for intrahepatic cholestasis during pregnancy.

CMOC Group Limited (03993) will distribute a final dividend of HKD 2.86 for every 10 shares.

FUDANZHANGJIANG (01349) has subscribed to 2.10 billion yuan of Shanghai Pudong Development Bank's structured deposit product.

ASCLETIS-B(01672): Clinical development of a fixed-dose combination formulation of ASC30, a once-daily oral small molecule GLP-1R agonist, and ASC39, a once-daily oral small molecule selective insulin receptor agonist.

CMOC Group Limited (03993) will distribute a final dividend of HKD 2.86 for every 10 shares.

FUDANZHANGJIANG (01349) has subscribed to 2.10 billion yuan of Shanghai Pudong Development Bank's structured deposit product.